The Association between Charlson Comorbidity Index and the Medical Care Cost of Cancer: A Retrospective Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Seok-Jun | - |
dc.contributor.author | Kim, Eun-Jung | - |
dc.contributor.author | Seo, Hyun-Ju | - |
dc.contributor.author | Oh, In-Hwan | - |
dc.date.accessioned | 2021-12-26T11:40:35Z | - |
dc.date.available | 2021-12-26T11:40:35Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 2314-6133 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/133197 | - |
dc.description.abstract | Background. This study compared comorbidity-related medical care cost associated with different types of cancer, by examining breast (N = 287), colon (N = 272), stomach (N = 614), and lung (N = 391) cancer patients undergoing surgery. Methods. Using medical benefits claims data, we calculated Charlson Comorbidity Index (CCI) and total medical cost. The effect of comorbidity on the medical care cost was investigated using multiple regression and logistic regression models and controlling for demographic characteristics and cancer stage. Results. The treatment costs incurred by stomach and colon cancer patients were 1.05- and 1.01-fold higher, respectively, in patients with higher CCI determined. For breast cancer, the highest costs were seen in those with chronic obstructive pulmonary disease (COPD), but the increase in cost reduced as CCI increased. Colon cancer patients with diabetes mellitus and a CCI = 1 score had the highest medical costs. The lowest medical costs were incurred by lung cancer patients with COPD and a CCI = 2 score. Conclusion. The comorbidities had a major impact on the use of medical resources, with chronic comorbidities incurring the highest medical costs. The results indicate that comorbidities affect cancer outcomes and that they must be considered strategies mitigating cancer's economic and social impact. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | HINDAWI LTD | - |
dc.subject | BREAST-CANCER | - |
dc.subject | CLAIMS DATA | - |
dc.subject | MORTALITY | - |
dc.subject | OUTCOMES | - |
dc.subject | DISEASE | - |
dc.subject | RECORDS | - |
dc.subject | KOREA | - |
dc.subject | RISK | - |
dc.subject | NEED | - |
dc.title | The Association between Charlson Comorbidity Index and the Medical Care Cost of Cancer: A Retrospective Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Seok-Jun | - |
dc.identifier.doi | 10.1155/2015/259341 | - |
dc.identifier.scopusid | 2-s2.0-84939504285 | - |
dc.identifier.wosid | 000359578400001 | - |
dc.identifier.bibliographicCitation | BIOMED RESEARCH INTERNATIONAL, v.2015 | - |
dc.relation.isPartOf | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.title | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.volume | 2015 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | RECORDS | - |
dc.subject.keywordPlus | KOREA | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | NEED | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | CLAIMS DATA | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.